Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
Study of Quality of Life, Safety and Compliance During Treatment of Schizophrenia or Bipolar Affective Disorder, in Patients Using the Drug Kvepin® (Quetiapine) as Monotherapy or Combination Therapy With Other Antipsychotics (Ispitivanje Kvalitete života, Sigurnosti i Saradljivosti u Toku liječenja Shizofrenije Ili Bipolarnog Afektivnog poremećaja, Kod Pacijenata Koji Koriste Lijek Kvepin® (Kvetiapin) Kao Monoterapiju Ili Kombinovanu Terapiju sa Drugim Antipsihoticima)
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in combination with another antipsychotic/antipsychotics. The main outcome measures are:
- quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)
- safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction
- therapy adherence using the Medication Adherence Rating Scale (MARS).
The subjects will be divided into two groups:
-
Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder whose individual therapeutic approach, based on the clinical assessment of the research physician, includes one of the following therapies:
- monotherapy with the drug quetiapine
- combined antipsychotic therapy with quetiapine and aripiprazole
- combined antipsychotic therapy with quetiapine and haloperidol
-
Patients with a diagnosis of schizophrenia or bipolar affective disorder who are on therapy with one of the antipsychotics (aripiprazole or haloperidol), and who, based on the clinical assessment of the investigator, require adjunctive quetiapine therapy. This group will include two subgroups of patients:
- combined antipsychotic therapy with quetiapine and aripiprazole
- combined antipsychotic therapy with quetiapine and haloperidol Recruitment of subjects will be carried out by physicians/researchers based on the patient's history and diagnosis. The diagnosis of schizophrenia or bipolar affective disorder will be based on the standard diagnostic criteria in medical practice (validated measurement scales in psychiatry - Young's Mania Scale, Beck Depression Scale and PANNS Schizophrenia Scale).
Patients will have four visits to physician/researcher:
- First visit - baseline at which patient will be included in the study
- Second visit - 4 months after the baseline
- Third visit - 8 months after the baseline
- Fourth visit - 12 months after the baseline
연구 개요
상태
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Halima Karakaš
- 전화번호: +38762478535
- 이메일: HalimaK@Bosnalijek.ba
연구 연락처 백업
- 이름: Una Glamoclija, PhD
- 전화번호: +38761147401
- 이메일: UnaG@Bosnalijek.ba
연구 장소
-
-
-
Sarajevo, 보스니아 헤르체고비나, 71000
- 모병
- Clinic of Psychiatry, University Clinical Center of Sarajevo
-
연락하다:
- Gorana Sulejmanpašić, PhD
- 전화번호: +38733297359
- 이메일: psihijatrija@kcus.ba
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Schizophrenia or bipolar affective disorder patients of both sexes aged 18 to 65 years.
설명
Inclusion Criteria:
- Persons over 18 years of age and under 65 years of age.
- Schizophrenia or bipolar affective disorder established by the usual diagnostic criteria applied in a psychiatric clinic or hospital ward/unit within the clinic or outpatient.
- Patients who are treated as outpatients, inpatients or have been discharged from the clinic/hospital with a recommendation for quetiapine monotherapy or combination therapy of quetiapine with aripiprazole or haloperidol. Recommended by a specialist psychiatrist/neuropsychiatrist in clinical and hospital centers and through specialist-consultant outpatient clinics in Bosnia and Herzegovina.
Exclusion Criteria:
- Persons younger than 18 years and older than 65 years
- Hypersensitivity to the components of the drug
- Positive history of angioneurotic edema
- Pregnancy
- Breastfeeding
- Simultaneous use with cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone
- Patients who are planning to become pregnant in the near future
- Diagnosed medical conditions that may constitute a contraindication for the use of the drug quetiapine
Withdrawal Criteria:
- Deterioration of the underlying disease that requires therapy discontinuation
- Development of serious adverse events requiring therapy discontinuation
- Occurence of pregnancy
- Development of another disease that affects the course of the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Newly diagnosed patients
Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder |
Monotherapy with the drug quetiapine Combined antipsychotic therapy with quetiapine and aripiprazole Combined antipsychotic therapy with quetiapine and haloperidol |
|
Previously diagnosed patients
Patients with a previous diagnosis of schizophrenia or bipolar affective disorder |
Combined antipsychotic therapy with quetiapine and aripiprazole Combined antipsychotic therapy with quetiapine and haloperidol |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Measurement of quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)-BREF
기간: 12 months from inclusion into the study (baseline)
|
Evaluation of the quality of life of patients during treatment for schizophrenia or bipolar affective disorder using monotherapy with the drug quetiapine or combination therapy with the drug quetiapine and another antipsychotic (aripiprazole or haloperidol). World Health Organization Quality of Life questionnaire (WHOQOL)-BREF will be used. It consists of 26 items that evaluate an individual's perception of their quality of life and consists of four domains: physical health (e.g., pain, energy, sleep, mobility, activities of daily living, work capacity); psychological health (e.g., positive and negative feelings, self-esteem, body image, cognition, spirituality); social relationships (e.g., personal relationships and social support) and environment. Domain scores are calculated according to the WHO scoring guidelines and can be transformed to a 0-100 scale, where higher scores represent a better quality of life. |
12 months from inclusion into the study (baseline)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety assessment through incidence of possible adverse drug events and evaluation of the association between the administration of the drug and the occurrence of an adverse reaction
기간: 12 months from baseline
|
Safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction |
12 months from baseline
|
|
Therapy adherence using the Medication Adherence Rating Scale (MARS)
기간: 12 months from baseline
|
Medication Adherence Rating Scale (MARS), a validated self-report questionnaire designed to evaluate patients' adherence to prescribed medication regimens. The instrument was originally developed for patients receiving long-term pharmacological treatment and has been widely used in studies of psychiatric and chronic medical conditions. The MARS consists of 10 items that assess both medication-taking behavior and patients' attitudes toward medication, including forgetfulness, intentional omission of doses, discontinuation of treatment when feeling better or worse, and beliefs regarding the effects of medication. Responses are provided in a dichotomous (Yes/No) format. Individual item scores are summed to obtain a total score ranging from 0 to 10, with higher scores indicating better medication adherence. The scale enables the identification of both intentional and unintentional non-adherence and provides insight into factors affecting treatment adherence. |
12 months from baseline
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Gorana Sulejmanpašić, PhD, Clinic of Psychiatry, University Clinical Center of Sarajevo
- 수석 연구원: Amra Memić Serdarević, PhD, Clinic of Psychiatry, University Clinical Center of Sarajevo
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- KVP-01-2024
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .